These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

884 related items for PubMed ID: 16102833

  • 1. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD, Pflugfelder SC, Tauber J, Foulks GN.
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME.
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E, Asfuroğlu E.
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D, Tauber J, Reis BL.
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN.
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [Abstract] [Full Text] [Related]

  • 10. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY, Perry HD, Barsam A, Perry AR, Donnenfeld ED, Wittpenn JR, D'Aversa G.
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE, Perry HD.
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
    Kujawa A, Rózycki R.
    Klin Oczna; 2005 Jan; 107(4-6):280-6. PubMed ID: 16118939
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.
    Chiang TH, Walt JG, McMahon JP, Mansfield JE, Simonyi S.
    Can J Clin Pharmacol; 2007 Jan; 14(2):e240-5. PubMed ID: 17622671
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.